Veracyte Announces Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Veracyte, Inc (VCYT) PT Raised to $55 at Needham & Company
July 30, 2021 6:28 AM EDTNeedham & Company analyst Mike Matson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $55.00 (from $54.00) while maintaining a Buy rating.
The analyst commented, "VCYT's 2Q21 revenue and EPS beat consensus. Organic revenue growth improved to 77% in 2Q21 from 5.7% in 1Q21 as... More
Veracyte (VCYT) Tops Q2 EPS by 12c
July 29, 2021 4:26 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.13), $0.12 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $55.1 million versus the consensus estimate of $48.06 million.
GUIDANCE:
Veracyte sees FY2021 revenue of $200-208 million, versus the consensus of $197.9... More
